Exactech, Inc. (EXAC) Receives $42.00 Consensus Price Target from Analysts

Shares of Exactech, Inc. (NASDAQ:EXAC) have received an average rating of “Hold” from the six analysts that are covering the stock, Marketbeat.com reports. One equities research analyst has rated the stock with a sell recommendation and four have assigned a hold recommendation to the company. The average twelve-month price target among analysts that have issued a report on the stock in the last year is $42.00.

Several equities analysts recently issued reports on EXAC shares. Zacks Investment Research cut Exactech from a “hold” rating to a “sell” rating in a research note on Wednesday, October 25th. BidaskClub cut Exactech from a “hold” rating to a “sell” rating in a research note on Monday, July 31st. Gabelli cut Exactech from a “buy” rating to a “hold” rating in a research note on Tuesday, October 24th. Robert W. Baird cut Exactech from an “outperform” rating to a “neutral” rating and set a $42.00 price objective on the stock. in a research note on Monday, October 23rd. Finally, Sidoti cut Exactech from a “buy” rating to a “neutral” rating in a research note on Monday, October 23rd.

Hedge funds have recently bought and sold shares of the business. Bank of Montreal Can bought a new stake in Exactech in the second quarter valued at $134,000. Russell Investments Group Ltd. lifted its stake in Exactech by 13.2% in the second quarter. Russell Investments Group Ltd. now owns 47,118 shares of the medical equipment provider’s stock valued at $1,405,000 after buying an additional 5,485 shares during the last quarter. OxFORD Asset Management LLP lifted its stake in Exactech by 17.8% in the second quarter. OxFORD Asset Management LLP now owns 59,972 shares of the medical equipment provider’s stock valued at $1,787,000 after buying an additional 9,082 shares during the last quarter. Prudential Financial Inc. bought a new stake in Exactech in the second quarter valued at $359,000. Finally, Schwab Charles Investment Management Inc. lifted its stake in Exactech by 30.3% in the second quarter. Schwab Charles Investment Management Inc. now owns 70,248 shares of the medical equipment provider’s stock valued at $2,094,000 after buying an additional 16,330 shares during the last quarter. Institutional investors own 64.58% of the company’s stock.

WARNING: “Exactech, Inc. (EXAC) Receives $42.00 Consensus Price Target from Analysts” was published by Sports Perspectives and is the sole property of of Sports Perspectives. If you are reading this piece on another website, it was illegally stolen and reposted in violation of United States and international copyright laws. The original version of this piece can be accessed at https://sportsperspectives.com/2017/11/22/exactech-inc-exac-receives-42-00-consensus-price-target-from-analysts.html.

Exactech (NASDAQ EXAC) traded down $0.05 during mid-day trading on Friday, hitting $41.75. 69,600 shares of the stock were exchanged, compared to its average volume of 63,680. Exactech has a twelve month low of $23.30 and a twelve month high of $42.75. The company has a debt-to-equity ratio of 0.06, a current ratio of 4.08 and a quick ratio of 2.09. The firm has a market capitalization of $600.51, a P/E ratio of 34.54, a P/E/G ratio of 3.59 and a beta of 1.04.

Exactech (NASDAQ:EXAC) last announced its quarterly earnings data on Monday, October 30th. The medical equipment provider reported $0.20 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $0.23 by ($0.03). Exactech had a return on equity of 7.22% and a net margin of 0.18%. The firm had revenue of $61.40 million for the quarter, compared to the consensus estimate of $61.78 million. research analysts forecast that Exactech will post 1.29 EPS for the current fiscal year.

Exactech Company Profile

Exactech, Inc develops, manufactures, markets, distributes and sells orthopedic implant devices, related surgical instrumentation and biologic services to hospitals and physicians. The Company’s segments include knee, hip, biologics and spine, extremity and other products. Its other products segment includes miscellaneous sales categories, such as bone cement, instrument rental fees, shipping charges and other product lines.

Receive News & Ratings for Exactech Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exactech Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply